Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome Proceeds from follow-on offering along with...
November 02, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8

DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
October 26, 2022 19:54 ET | Source: Taysha Gene Therapies, Inc.

Taysha Announces Pricing of Public Offering of Common Stock

DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing...
October 25, 2022 16:01 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Announces Proposed Public Offering of Common Stock

DALLAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
October 24, 2022 19:35 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Host Conference Call to Discuss Astellas Pharma’s Strategic Investment to Support the Development of Taysha’s AAV-based Gene Therapy Programs

DALLAS, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
October 24, 2022 19:30 ET | Source: Taysha Gene Therapies, Inc.

Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs

- Taysha Gene Therapies is an emerging leader in the development of AAV gene therapies; new collaboration aimed at enhancing development of two of Taysha’s novel product candidates for rare monogenic...
October 06, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Announces Presentations at the Upcoming 29th Annual Meeting of the European Society of Gene & Cell Therapy (ESGCT)

DALLAS, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
August 11, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update

TSHA-120 treated patients in GAN demonstrated durable improvement and recoverability of sensory nerve amplitude potential (SNAP), a definitive clinical endpoint, compared to natural history TSHA-120...
August 09, 2022 17:22 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Release Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11

DALLAS, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
August 01, 2022 07:00 ET | Source: Taysha Gene Therapies, Inc.

Taysha Gene Therapies to Participate in Upcoming August Investor Conferences

BTIG Biotechnology Conference on August 8, 2022 at 12:00 pm ET 2022 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2022 at 9:45 am ET DALLAS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Taysha...